Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Phase 1
2 (66.7%)phase_1_2
1 (33.3%)Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
Phase 1
Recruiting
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- eyeDNA Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT03328130
- Locations
- π«π·
Clinique Ophtalmologique, CHU de Nantes, Nantes, France
News
EyeDNA's HORA-PDE6b Receives FDA Rare Pediatric Disease Designation for PDE6b Retinitis Pigmentosa
EyeDNA Therapeutics' HORA-PDE6b, a novel gene therapy, has received Rare Pediatric Disease Designation from the FDA for PDE6b-related retinitis pigmentosa.